Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NRG Energy Inc (NRG) vs Sana Biotechnology Inc (SANA) Price & Performance

NRG Energy IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

NRG Energy Inc vs Sana Biotechnology Inc — how do they compare? NRG Energy Inc trades at $116.91 (market cap $25.15B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: NRG Energy Inc is far larger — about 24.4× Sana Biotechnology Inc's market cap, and NRG Energy Inc pays a 1.59% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

NRGSANA
Market Cap
$25.15B$1.03B
Sector
UtilitiesHealth
52-Week High
$184.03$5.92
52-Week Low
$109.51$2.68
Enterprise Value
$49.10B$946.04M
Dividend Yield
1.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NRG Energy Inc

NRG Energy trades at $119.64, up 0.52% with a bullish technical signal despite recent earnings misses. The stock shows strong profitability metrics including 26.77% ROE and 2.56% net margin, supported by $30.71B revenue in 2025. Recent developments include a transformative 1.2 GW Texas data-center power project and LS Power acquisition, driving long-term growth expectations. Cash flow trends show volatility with 2025 net cash flow of $3.83B followed by projected 2026 outflow of -$264M.

Wall Street maintains strong bullish sentiment with 69% buy ratings and $201.29 consensus target, representing 68% upside. Key risks include rising interest costs impacting earnings, elevated debt levels at 56.42% debt-to-asset ratio, and execution challenges with major capital projects. The data center expansion strategy offers significant growth potential but requires careful monitoring of capex and leverage management.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.

Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About NRG Energy Inc

NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.

Read more on NRG

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA